Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Newborn Screening Market Size to Hit USD 2.14 Billion by 2035, at a CAGR of 7.68% - SNS Insider

globenewswire.com
WAT Waters Corporation is highlighted as a dominant supplier of tandem mass spectrometry instruments for newborn screening laboratories, indicating a positive outlook in this growing market. BIO Bio-Rad Laboratories is noted as a primary domestic supplier of U.S. screening instruments and reagents, and a leader in immunoassay and molecular assay reagent supply for the expanding newborn screening market. SCI SCIEX is mentioned as contributing additional analytical instrumentation to the newborn screening market, without specific positive or negative sentiment.

Newborn Screening Market Size to Hit USD 2.14 Billion by 2035, at a CAGR of 7.68% - SNS Insider Austin, United States, Sept. 02, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Newborn Screening Market was valued at USD 1.02 Billion in 2025 and is expected to reach USD 2.14 Billion by 2035, growing at a CAGR of 7.68% from 2026 to 2035. Demand is increasing due to mandatory universal testing by the governments, increasing parental awareness of avoidable genetic diseases, and increasing number of disease panels in the national screening panel. The U.S., Germany, and Japan topped the list in 2023 due to having highly established screening programs with wide disease panels.

The next generation of sequencing techniques, artificial intelligence-powered analytics, and point-of-care screening kits have played an important part in the development of newborn screening technology, which is happening due to increased demands for specialized enzyme and molecular assays for spinal muscular atrophy and severe combined immunodeficiency.

Download the Newborn Screening Market Sample Report: https://www.snsinsider.com/sample-request/5787

Newborn Screening Market Key Highlights

Market Relevance

The use of newborn screening has become an indispensable part of modern-day public health practice due to the fact that there is a need for systematic and technology-oriented methods to screen for certain genetic, metabolic, endocrine and congenital disorders right after birth. Early identification of such conditions will facilitate early initiation of treatment before permanent injury, disability or even death takes place from disorders like phenylketonuria, congenital hypothyroidism, sickle cell disease, cystic fibrosis and spinal muscular atrophy.

Newborn Screening Market Overview

The marketplace consists of tandem mass spectrometry, DNA tests and next generation sequencing, and dry blood spot tests and critical congenital heart disease tests that have been employed in hospitals and diagnostic centers. Tandem mass spectrometry is still the key method in screening for metabolic disorders, allowing the quantitation of more than 40 amino acids, acyl carnitines, and organic acids from a single dried blood spot within less than two minutes of instrumental analysis. DNA testing and next generation sequencing have gained popularity in detecting those disorders which are not detected by metabolite testing such as SCID, SMA, and LSDs.

Strategic Market Outlook

There is potential in whole-genome and whole-exome sequencing of newborns’ dried blood spots samples, allowing simultaneous detection of thousands of genetic diseases at costs that approach USD 200 per sample. National pilot newborn genomics screening programs implemented in the United States, United Kingdom, and Australia are accumulating evidence on clinical utility of these tests, providing a catalyst for further regulation and policy, while biobanking of dried blood spots provides another potential for retroactive genomic studies.

A high false-positive rate for each test and the lack of facilities for follow-up and confirmatory testing are significant limitations in developing countries. The inclusion of each additional disease in the panel of screening diseases means addition of its own false-positive rate, adding up to the overall burden for metabolic specialists who would have to conduct the follow-up testing, while lack of confirmatory testing labs and infrastructure for treatment in some regions of Asia, Africa, and Latin America makes expansion of such programs infeasible.

Newborn Screening Market Regional Analysis

North America held approximately 41% of the global market in 2025, making it the largest region. The United States accounts for approximately 82.6% of North American revenue, supported by its comprehensive mandatory state screening programmes and the world's broadest RUSP panel.

The U.S. Newborn Screening Market was valued at approximately USD 335.5 Million in 2025 and is expected to reach approximately USD 702.3 Million by 2035, growing at a CAGR of approximately 7.68%, aided by the Recommended Uniform Screening Panel covering 35 core and 26 secondary conditions.

The Europe Newborn Screening Market was worth USD 0.31 Billion in 2025 and is anticipated to reach USD 0.62 Billion by 2035, expanding at a CAGR of 7.40% from 2026 to 2035. Germany accounted for approximately 23.8% of European revenue in 2025, supported by a comprehensive tandem mass spectrometry panel covering 14 core disorders.

The Asia-Pacific region is the fastest-growing, driven by large birth cohorts across China, India, Japan, and Southeast Asia. China contributed approximately 42.4% of regional revenue in 2025 through its national newborn screening programme's multi-disorder TMS panel adoption.

Middle East & Africa: Saudi Arabia leads regional demand at approximately 28.4% of regional revenue in 2025.

Latin America: Brazil leads regional demand at approximately 43.8% of regional revenue in 2025.

Buy the Newborn Screening Market Report with Competitive Analysis and 2035 Forecast: https://www.snsinsider.com/checkout/5787

Newborn Screening Market Segment Analysis

By Technology: Tandem Mass Spectrometry held about 42.3% market share in 2025, as it enables the quantification of more than 40 amino acids, acylcarnitines, and organic acids through a single dried blood spot. DNA Assays & Next-Generation Sequencing is the fastest growing segment with about 11.2% CAGR, due to the detection of conditions that cannot be detected through metabolites.

By Test Type: Dry blood spot tests accounted for around 62.5% market share in 2025. Critical congenital heart disease testing is the fastest-growing segment, at around 9.8% CAGR.

By Disorder Type: Market share of metabolic disorders in 2025 was estimated at approximately 38.7%, owing to the critical nature of amino acid, fatty acid oxidation, and organic acid disorder testing. Immune deficiency disorders are the most rapidly growing segment, owing to expanding SCID and SMA screening regulations.

By End User: Hospitals constituted about 51.2% market share in 2025. Diagnostic centers is the fastest growing segment, with about 9.4% CAGR.

Newborn Screening Market Key Trends

Competitive Landscape

The Newborn Screening Market includes established laboratory instrument manufacturers, diagnostic reagent suppliers, and genomic technology developers, with competition centred on tandem mass spectrometry, molecular assay expansion, and next-generation sequencing capability.

PerkinElmer and Waters Corporation dominate tandem mass spectrometry instrument supply for newborn screening laboratories, while PerkinElmer, Bio-Rad Laboratories, and Natus Medical provide the primary domestic supply of U.S. screening instruments and reagents. Bio-Rad Laboratories leads immunoassay and molecular assay reagent supply, and SCIEX and Agilent Technologies contribute additional analytical instrumentation to the competitive landscape.

Major key players include

Explore the Complete Newborn Screening Market Report: https://www.snsinsider.com/reports/newborn-screening-market-5787